Mereo BioPharma Group plc (LON:0A9G)

London flag London · Delayed Price · Currency is GBP · Price in USD
2.805
-0.014 (-0.50%)
At close: Jun 20, 2025
-30.48%
Market Cap 322.69M
Revenue (ttm) n/a
Net Income (ttm) -36.52M
Shares Out n/a
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 8,141
Average Volume 7,027
Open 3.010
Previous Close 2.819
Day's Range 2.775 - 3.010
52-Week Range 1.579 - 5.009
Beta 0.35
RSI 60.89
Earnings Date Aug 13, 2025

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2015
Employees 36
Stock Exchange London Stock Exchange
Ticker Symbol 0A9G
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.